Clene to Present at the Canaccord 45th Annual Growth Conference
Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company specializing in neurodegenerative disease treatments, will present at the Canaccord 45th Annual Growth Conference on August 12th, 2025, at 3:30pm ET in Boston, MA.
The company, which focuses on developing treatments for amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), will conduct a presentation and host one-on-one investor meetings. A webcast will be available through the company's website and online registration.
Clene (NASDAQ: CLNN), un'azienda biofarmaceutica in fase clinica avanzata specializzata in trattamenti per malattie neurodegenerative, presenter脿 al Canaccord 45th Annual Growth Conference il 12 agosto 2025 alle 15:30 ET a Boston, MA.
L'azienda, focalizzata sullo sviluppo di terapie per la sclerosi laterale amiotrofica (SLA) e la sclerosi multipla (SM), terr脿 una presentazione e organizzer脿 incontri individuali con gli investitori. Una trasmissione in diretta sar脿 disponibile tramite il sito web dell'azienda e la registrazione online.
Clene (NASDAQ: CLNN), una empresa biofarmac茅utica en etapa cl铆nica avanzada especializada en tratamientos para enfermedades neurodegenerativas, presentar谩 en la 45陋 Conferencia Anual de Crecimiento Canaccord el 12 de agosto de 2025 a las 3:30 pm ET en Boston, MA.
La compa帽铆a, que se centra en desarrollar tratamientos para la esclerosis lateral amiotr贸fica (ELA) y la esclerosis m煤ltiple (EM), realizar谩 una presentaci贸n y llevar谩 a cabo reuniones individuales con inversores. Habr谩 una transmisi贸n web disponible a trav茅s del sitio web de la empresa y el registro en l铆nea.
Clene (NASDAQ: CLNN)電� 鞁犼步韲错枆靹� 歆堩櫂 旃橂鞝滊ゼ 鞝勲鞙茧 頃橂姅 頉勱赴 鞛勳儊 雼硠 氚旍澊鞓れ牅鞎� 須岇偓搿�, 2025雲� 8鞗� 12鞚� 鞓ろ泟 3鞁� 30攵�(霃欕秬鞁滉皠)鞐� 氤挫姢韯�, MA鞐愳劀 鞐措Μ電� Canaccord 鞝�45須� 鞐半 靹膘灔 旎嵓霟办姢鞐愳劀 氚滍憸頃� 鞓堨爼鞛呺媹雼�.
鞚� 須岇偓電� 攴检渼於曥劚 旄§偔 瓴巾檾歃�(ALS)瓿� 雼る皽靹� 瓴巾檾歃�(MS) 旃橂鞝� 臧滊皽鞐� 欤茧牓頃橁碃 鞛堨溂氅�, 氚滍憸毳� 歆勴枆頃橁碃 1:1 韴瀽鞛� 氙疙寘鞚� 臧滌禍頃� 鞓堨爼鞛呺媹雼�. 鞗轨簮鞀ろ姼電� 須岇偓 鞗轨偓鞚错姼鞕� 鞓澕鞚� 霌彪鞚� 韱淀暣 鞝滉车霅╇媹雼�.
Clene (NASDAQ : CLNN), une soci茅t茅 biopharmaceutique en phase clinique avanc茅e sp茅cialis茅e dans les traitements des maladies neurod茅g茅n茅ratives, pr茅sentera lors de la 45e conf茅rence annuelle sur la croissance Canaccord le 12 ao没t 2025 脿 15h30 ET 脿 Boston, MA.
La soci茅t茅, qui se concentre sur le d茅veloppement de traitements pour la scl茅rose lat茅rale amyotrophique (SLA) et la scl茅rose en plaques (SEP), fera une pr茅sentation et organisera des rencontres individuelles avec des investisseurs. Une webdiffusion sera disponible via le site internet de la soci茅t茅 et l'inscription en ligne.
Clene (NASDAQ: CLNN), ein biopharmazeutisches Unternehmen in der sp盲ten klinischen Phase, das sich auf Behandlungen neurodegenerativer Erkrankungen spezialisiert hat, wird auf der Canaccord 45th Annual Growth Conference am 12. August 2025 um 15:30 Uhr ET in Boston, MA, pr盲sentieren.
Das Unternehmen, das sich auf die Entwicklung von Therapien f眉r amyotrophe Lateralsklerose (ALS) und multiple Sklerose (MS) konzentriert, wird eine Pr盲sentation halten und Einzelgespr盲che mit Investoren f眉hren. Ein Webcast wird 眉ber die Website des Unternehmens und die Online-Registrierung verf眉gbar sein.
- None.
- None.
SALT LAKE CITY, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, 鈥淐lene鈥�) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that management will present at the Canaccord 45th Annual Growth Conference and host 1x1 investor meetings.
Date: August 12th, 2025
Time of Presentation: 3:30pm ET
Location: Boston, MA
Format: Presentation
1x1 Meetings: Please contact your Canaccord representative
A webcast of the presentation will be available on the 鈥溾�� section of the Clene website. Alternatively, one can register online to view the webcast here: .
About Clene
Clene Inc., (Nasdaq: CLNN) (along with its subsidiaries, 鈥淐lene鈥�) and its wholly owned subsidiary Clene Nanomedicine Inc., is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson鈥檚 disease, and multiple sclerosis. CNM-Au8庐聽is an investigational first-in-class therapy that improves central nervous system cells鈥� survival and function via a mechanism that targets mitochondrial function and the NAD pathway while reducing oxidative stress. CNM-Au8庐聽is a federally registered trademark of Clene Nanomedicine, Inc. The company is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland. For more information, please visit聽聽or follow us on聽听补苍诲听.
Investor Contact
Kevin Gardner
LifeSci Advisors
617-283-2856
FAQ
When and where will Clene (CLNN) present at the Canaccord Growth Conference?
What diseases does Clene (CLNN) focus on treating?
How can investors access Clene's Canaccord conference presentation?
What type of meetings will Clene (CLNN) host at the Canaccord conference?
